Net Loss per Share

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Notes to Financial Statements

Net Loss per Share

The Company calculates basic and diluted net loss per share using the weighted-average number of shares of common stock outstanding during the period.

When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods. If the Company was to be in a net income position, the weighted average number of shares used to calculate the diluted net income per share would include the potential dilutive effect of in-the-money securities, as determined using the treasury stock method.

The table below presents, after giving effect to the reverse split, the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.

	As of June 30,
	2016		2015
Stock options		632,310		384,195
Restricted stock awards		212,689		294,709
Preferred stock		2,792,190		3,128,108
Common stock warrants		1,199,505		805,361
Total		4,836,694		4,612,373

The Company calculates basic and diluted net loss per share using the weighted average number of shares of common stock outstanding during the period.

When the Company is in a net loss position, it excludes from the calculation of diluted net loss per share all potentially dilutive stock options, preferred stock and warrants, and the diluted net loss per share is the same as the basic net loss per share for such periods. If the Company was to be in a net income position, the weighted average number of shares used to calculate the diluted net income per share would include the potential dilutive effect of in-the-money securities, as determined using the treasury stock method.

The table below presents the potentially dilutive securities that would have been included in the calculation of diluted net loss per share if they were not antidilutive for the periods presented.

	Years Ended December 31,
	2015		2014
Stock options		438,248		6,030
MabVax Series A redeemable convertible preferred stock		—		18,596
MabVax Series B redeemable convertible preferred stock		—		21,114
MabVax Series C-1 redeemable convertible preferred stock		—		55,736
Series B redeemable convertible preferred stock		—		13,905
Series A-1 preferred stock		—		100,359
Series C preferred stock		—		6,355
Series D preferred stock		2,587,717		—
Series E preferred stock		450,446		—
Unvested restricted stock		310,926		—
Warrants to purchase common stock		974,280		—
Total		4,761,617		222,095